ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Friday, 26 July 2013

PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022 include new market research report"PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022 " to its huge collection of research reports.

GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines
Germany Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Germany and therefore is not expected to change drastically during the forecast period.


Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Germany from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Germany Meningococcal Vaccines market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Germany

For More Information Kindly Contact:


Post a Comment